Disclosed is a method for preparing an insulin glargine (GlyA 21 -Arg B31 -Ary B32 - human insulin) crystal, comprising crystallizing the insulin glargine at pH 7.0-9.0 and in a crystallization solution containing a recombinant insulin glargine, an organic solvent of a 10-30% concentration by volume, a zinc compound, a phenol derivative, a salt and an organic acid.

Disclosed is a preparation method for an insulin glargine (GlyA21-ArgB31-AryB32- human insulin) crystal, comprising crystallizing the insulin glargine in the crystal solution containing a recombinant insulin glargine, an organic solvent of a 10-30% concentration by volume, a zinc compound, a phenol derivative, a salt and an organic acid with a condition of pH 7.0-9.0.